On December 20, Glonghui reported that Changchun High-Tech Industries (000661.SZ) announced that its holding subsidiary - Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as "Baike Biotechnology") received the "Clinical Trial Approval Notification" issued by the National Medical Products Administration, and the clinical trial application for the type II herpes simplex virus mRNA vaccine has been approved. Type II herpes simplex virus infection causes genital herpes, an infectious disease primarily transmitted through sexual activity, which is easy to contract, recurs frequently, and has no effective cure, thus becoming a serious public health issue. To prevent the occurrence of genital herpes, several Biomedical companies have continuously focused on the research and development of herpes simplex virus vaccines.
The type II herpes simplex virus vaccine approved for clinical use by Baike Biotechnology is jointly submitted with Zhuhai Lifanda Biotechnology Co., Ltd. (Baike Biotechnology is the Hold of the license), and this vaccine is a multi-component vaccine that can simultaneously induce humoral immune response and cellular immune response, and utilizes the mRNA technology pathway to further enhance the cellular immune response, improving the likelihood of successful vaccine development compared to traditional technology pathways.
As of now, no related vaccine products have been successfully developed and marketed globally. If Baike Biotechnology's type II herpes simplex virus mRNA vaccine can be successfully developed, it will further enrich the company's product pipeline and better meet market demands.
